1.Date of occurrence of the event:2023/02/03
2.Company name:TaiMed Biologics Inc.
3.Relationship to the Company (please enter "head office" or
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:
WEP Clinical LTD (WEP), a specialist services company that works with
pharmaceutical companies to help patients and physicians gain access to
medicines when no other treatment options are available, has partnered with
TaiMed Biologics to launch a Named Patient Program (NPP) for TROGARZO, an
IV treatment administered every two weeks for patients with muti-drug
resistant HIV disease.
The NPP is designed to ensure that physicians in Europe and other regions
around the world, where TROGARZO is not commercially available, can request
TROGARZO on behalf of individual patients who have trouble achieving viral
suppression using standard HIV regimens.
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
The company terminated the Trogarzo exclusive marketing right in Europe with
Theratechnologies on November 1, 2022. TaiMed and WEP Clinical officially
signed the service contract for the Post-Approval Named Patient Program
(NPP) on December 8, 2022 to continue supplying Trogarzo for the need of
MDR patients in Europe and extend to global regions outside of the United
States and Canada.